Innovative Implant Uses Oxygenation to Treat Type 1 Diabetes
A new implant system developed at Cornell University offers a promising approach to treating type 1 diabetes by oxygenating insulin-producing cells, potentially reducing dependence on immunosuppressive drugs and enabling better disease management.
Researchers at Cornell University have developed a groundbreaking implant system designed to treat type 1 diabetes by enhancing oxygen supply to insulin-producing cells. This novel device delivers oxygen directly to densely packed pancreatic cells, allowing them to function effectively without needing immunosuppressive drugs. The system consists of a cylindrical capsule housing transplanted insulin-secreting cells and a compact electrochemical oxygen generator the size of a dime, which can be removed as needed. A nanofibrous membrane protects the cells from immune attacks, while a permeable membrane ensures the transfer of oxygen and nutrients.
The technology builds upon previous implantable devices developed in the lab of Professor Minglin Ma, who has previously achieved success controlling blood sugar in diabetic mice but faced limitations due to oxygen deprivation leading to cell death. By introducing the oxygen generator, the new system maintains an adequate oxygen supply, significantly prolonging the survival and functionality of transplanted cells.
The device has been successfully tested in rat models, demonstrating its potential to support high-density cell transplantation and immune protection. Future steps include testing in pig models and exploring applications for other chronic diseases requiring local delivery of therapeutic molecules.
This approach could revolutionize treatment options for the approximately 2 million people with type 1 diabetes in the U.S., enabling more effective and potentially curative therapies without the risks associated with immune suppression. The implant's ability to provide tighter sugar control could allow patients to manage their condition naturally, with fewer daily interventions.
The system's innovative design emphasizes immune protection, efficient oxygenation, and compatibility with long-term use, paving the way for advanced cell therapies. The research team is also exploring broader applications, including delivering other therapeutic proteins and addressing autoimmune and inflammatory diseases.
Source: https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Nirsevimab Shows Promise in Protecting Infants from RSV Lower Respiratory Tract Disease
A new study confirms that nirsevimab provides strong protection for infants against RSV-related lower respiratory tract disease, significantly reducing hospitalizations and healthcare visits during the RSV season.
Promising Diabetes Medication Demonstrates Anti-Aging Benefits in Patients with Type 2 Diabetes
A recent study reveals that henagliflozin, a common diabetes medication, may also promote cellular aging reduction by increasing telomere length in patients with type 2 diabetes, offering potential anti-aging benefits.
Essential Tips for Staying Safe During Heat Waves and Recognizing Heat Stroke Signs
Learn essential tips to stay safe during heat waves, recognize early signs of heat exhaustion and heat stroke, and protect vulnerable populations from extreme heat risks this summer.
Work Requirements and Bureaucratic Challenges for Millions on Medicaid
New Medicaid work requirements in many states are creating confusing processes, risking loss of coverage for millions. Experts warn about increased red tape and systemic hurdles that hinder access to essential health coverage.